Published in J Mol Model on January 04, 2011
VMD: visual molecular dynamics. J Mol Graph (1996) 117.02
Scalable molecular dynamics with NAMD. J Comput Chem (2005) 59.49
SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis (1997) 57.27
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics (2005) 34.83
Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins (2003) 32.38
SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res (2003) 25.86
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32
I-TASSER server for protein 3D structure prediction. BMC Bioinformatics (2008) 18.28
TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res (2005) 14.15
Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature (2007) 14.06
GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (2007) 11.74
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
Scoring function for automated assessment of protein structure template quality. Proteins (2004) 10.99
The structure and function of G-protein-coupled receptors. Nature (2009) 8.08
Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics (2005) 6.82
Template-based modeling and free modeling by I-TASSER in CASP7. Proteins (2007) 6.45
A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem (1985) 6.09
A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure (2008) 6.01
Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci (2007) 5.18
Ab initio modeling of small proteins by iterative TASSER simulations. BMC Biol (2007) 5.07
Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature (2010) 3.19
A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem (1993) 2.78
Identification of two distinct inactive conformations of the beta2-adrenergic receptor reconciles structural and biochemical observations. Proc Natl Acad Sci U S A (2009) 2.77
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol (2005) 2.73
Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol (2006) 2.69
Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem (2005) 2.64
Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc (2010) 2.62
G protein coupled receptor structure and activation. Biochim Biophys Acta (2006) 2.48
Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci (2009) 2.33
Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. J Mol Recognit (2009) 2.05
Beta 2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation. Naunyn Schmiedebergs Arch Pharmacol (1987) 1.98
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol (2004) 1.95
L-type calcium current and contractility in ventricular myocytes from mice overexpressing the cardiac beta 2-adrenoceptor. Cardiovasc Res (1999) 1.61
(PS)2: protein structure prediction server. Nucleic Acids Res (2006) 1.59
Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. J Med Chem (2008) 1.59
Insights into signaling from the beta2-adrenergic receptor structure. Nat Chem Biol (2008) 1.56
The affinity of (-)-propranolol for beta 1- and beta 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch Pharmacol (1985) 1.55
On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. J Med Chem (2008) 1.46
Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation. Biophys J (2007) 1.37
Ligand binding and subtype selectivity of the human A(2A) adenosine receptor: identification and characterization of essential amino acid residues. J Biol Chem (2010) 1.37
Topology of class A G protein-coupled receptors: insights gained from crystal structures of rhodopsins, adrenergic and adenosine receptors. Mol Pharmacol (2008) 1.28
Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart. Mol Pharmacol (2004) 1.21
Site-directed mutagenesis of beta-adrenergic receptors. Identification of conserved cysteine residues that independently affect ligand binding and receptor activation. J Biol Chem (1989) 1.21
The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology. Pharmacol Ther (2008) 1.20
Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery. Biochemistry (2008) 1.19
Characterization and autoradiographic localization of beta-adrenoceptor subtypes in human cardiac tissues. Br J Pharmacol (1987) 1.18
The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol (2001) 1.18
G protein-coupled time travel: evolutionary aspects of GPCR research. Mol Interv (2007) 1.16
Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor. Br J Pharmacol (2002) 1.08
Role of group-conserved residues in the helical core of beta2-adrenergic receptor. Proc Natl Acad Sci U S A (2007) 1.02
Using guinea pigs in studies relevant to asthma and COPD. Pulm Pharmacol Ther (2008) 0.98
Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. Bioorg Med Chem Lett (2008) 0.94
Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. Clin Rev Allergy Immunol (2006) 0.92
Crystallizing thinking about the beta2-adrenergic receptor. Mol Pharmacol (2008) 0.90
Contribution of beta 1- and beta 2-adrenoceptors of human atrium and ventricle to the effects of noradrenaline and adrenaline as assessed with (-)-atenolol. Br J Pharmacol (1988) 0.90
Pharmacological characterisation of the beta-adrenoceptor expressed by human lung mast cells. Eur J Pharmacol (2002) 0.87
Computing highly correlated positions using mutual information and graph theory for G protein-coupled receptors. PLoS One (2009) 0.87
Anomalous equilibrium binding properties of high-affinity racemic radioligands. Mol Pharmacol (1981) 0.86
Profile of ligand binding to the porcine beta2-adrenergic receptor. J Anim Sci (2001) 0.85
Betablockers at work: the crystal structure of the beta2-adrenergic receptor. Angew Chem Int Ed Engl (2008) 0.83
Docking studies on a refined human beta(2) adrenoceptor model yield theoretical affinity values in function with experimental values for R-ligands, but not for S-antagonists. J Mol Model (2009) 0.80
Function of cardiac beta1- and beta2-adrenoceptors of newborn piglets: role of phosphodiesterases PDE3 and PDE4. Eur J Pharmacol (2010) 0.79
Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation. J Mol Graph Model (2006) 0.79
Characterization of porcine beta1- and beta2-adrenergic receptors in heart, skeletal muscle, and adipose tissue, and the identification of an atypical beta-adrenergic binding site. J Anim Sci (2005) 0.78
The functional role of beta-adrenoceptor subtypes in mediating relaxation of pig urethral smooth muscle. J Urol (2003) 0.78
Rapid communication: molecular cloning of the porcine beta 2-adrenergic receptor gene. J Anim Sci (1997) 0.76
Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist. Eur J Med Chem (2008) 0.76
Homology modeling and flex-ligand docking studies on the guinea pig beta(2) adrenoceptor: structural and experimental similarities/ differences with the human beta(2). J Mol Model (2009) 0.76
Scope and difficulty in generating theoretical insights regarding ligand recognition and activation of the beta 2 adrenergic receptor. J Med Chem (2010) 0.76
Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart. Mol Pharmacol (2004) 1.21
Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol (2002) 1.15
Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol (2004) 1.12
Appearance of a ventricular 5-HT4 receptor-mediated inotropic response to serotonin in heart failure. Cardiovasc Res (2005) 1.03
(-)-CGP 12177 increases contractile force and hastens relaxation of human myocardial preparations through a propranolol-resistant state of the beta 1-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol (2002) 1.02
Inotropy and L-type Ca2+ current, activated by beta1- and beta2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart. Br J Pharmacol (2009) 1.02
Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.00
Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.96
Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man. J Pharmacol Exp Ther (2008) 0.94
In vitro apoptotic activity of 2,2-diphenyl-1,3,2-oxazaborolidin-5-ones in L5178Y cells. Life Sci (2006) 0.92
Automated docking for novel drug discovery. Expert Opin Drug Discov (2013) 0.90
Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i). Naunyn Schmiedebergs Arch Pharmacol (2004) 0.90
Cardiostimulant and cardiodepressant effects through overexpressed human beta2-adrenoceptors in murine heart: regional differences and functional role of beta1-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.88
(-)-Adrenaline elicits positive inotropic, lusitropic, and biochemical effects through beta2 -adrenoceptors in human atrial myocardium from nonfailing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.88
Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. Biopolymers (2006) 0.88
Backbone conformational preferences of an intrinsically disordered protein in solution. Mol Biosyst (2012) 0.87
The existence of a second allosteric site on the M1 muscarinic acetylcholine receptor and its implications for drug design. Bioorg Med Chem Lett (2005) 0.87
PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. Br J Pharmacol (2013) 0.87
Human atrial β(1L)-adrenoceptor but not β₃-adrenoceptor activation increases force and Ca(2+) current at physiological temperature. Br J Pharmacol (2011) 0.86
Ontogenic changes of the control by phosphodiesterase-3 and -4 of 5-HT responses in porcine heart and relevance to human atrial 5-HT(4) receptors. Br J Pharmacol (2009) 0.86
Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle. Br J Pharmacol (2006) 0.86
Rolipram reduces the inotropic tachyphylaxis of glucagon in rat ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.85
Physiological antagonism between ventricular beta 1-adrenoceptors and alpha 1-adrenoceptors but no evidence for beta 2- and beta 3-adrenoceptor function in murine heart. Br J Pharmacol (2002) 0.85
Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.84
BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37). Br J Pharmacol (2002) 0.84
Anti-diarrheal activity of (-)-epicatechin from Chiranthodendron pentadactylon Larreat: experimental and computational studies. J Ethnopharmacol (2012) 0.83
Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.82
Exploration of human serum albumin binding sites by docking and molecular dynamics flexible ligand-protein interactions. Biopolymers (2010) 0.82
Transient stability of the helical pattern of region F19-L22 of the N-terminal domain of p53: a molecular dynamics simulation study. Biochem Biophys Res Commun (2006) 0.81
A computational analysis of the binding mode of closantel as inhibitor of the Onchocerca volvulus chitinase: insights on macrofilaricidal drug design. J Comput Aided Mol Des (2011) 0.81
Molecular modeling used to evaluate CYP2C9-dependent metabolism: homology modeling, molecular dynamics and docking simulations. Curr Drug Metab (2011) 0.81
Insights into the structural stability of Bax from molecular dynamics simulations at high temperatures. Protein Sci (2011) 0.80
Inhibition of influenza A virus infection in vitro by peptides designed in silico. PLoS One (2013) 0.80
Docking studies on a refined human beta(2) adrenoceptor model yield theoretical affinity values in function with experimental values for R-ligands, but not for S-antagonists. J Mol Model (2009) 0.80
Structural considerations for the rational design of selective anti-trypanosomal agents: the role of the aromatic clusters at the interface of triosephosphate isomerase dimer. Biochem Biophys Res Commun (2005) 0.80
Function of cardiac beta1- and beta2-adrenoceptors of newborn piglets: role of phosphodiesterases PDE3 and PDE4. Eur J Pharmacol (2010) 0.79
Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies. Appl Biochem Biotechnol (2014) 0.79
The importance of employing computational resources for the automation of drug discovery. Expert Opin Drug Discov (2015) 0.79
Docking and quantum mechanic studies on cholinesterases and their inhibitors. Eur J Med Chem (2006) 0.79
Theoretical study of 3-D molecular similarity and ligand binding modes of orthologous human and rat D2 dopamine receptors. Comput Biol Med (2011) 0.78
Homology modeling and molecular dynamics of CYP1A1 and CYP2B1 to explore the metabolism of aryl derivatives by docking and experimental assays. Eur J Med Chem (2010) 0.78
Mapping myeloperoxidase to identify its promiscuity properties using docking and molecular dynamics simulations. Curr Pharm Des (2013) 0.78
Aspartate138 is required for the high-affinity ligand binding site but not for the low-affinity binding site of the beta1-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.78
BIBN4096BS and CGRP(8-37) antagonize the relaxant effects of alpha-CGRP more than those of beta-CGRP in human extracranial arteries. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.77
Predicting peptide vaccine candidates against H1N1 influenza virus through theoretical approaches. Immunol Res (2015) 0.77
Exploring the possible binding sites at the interface of triosephosphate isomerase dimer as a potential target for anti-tripanosomal drug design. Bioorg Med Chem Lett (2004) 0.77
Fully flexible docking models of the complex between alpha7 nicotinic receptor and a potent heptapeptide inhibitor of the beta-amyloid peptide binding. Bioorg Med Chem Lett (2006) 0.77
Exploring QSARs for inhibitory effect of a set of heterocyclic thrombin inhibitors by multilinear regression refined by artificial neural network and molecular docking simulations. J Enzyme Inhib Med Chem (2011) 0.77
In silico and in vitro studies to elucidate the role of Cu2+ and galanthamine as the limiting step in the amyloid beta (1-42) fibrillation process. Protein Sci (2013) 0.77
5-Hydroxytryptamine-induced contraction of human temporal arteries coexpressing 5-HT2A receptors and wild-type or variant (Phe124Cys) 5-HT1B receptors: increased contribution of 5-HT1B receptors to the total contractile amplitude in arteries from Phe124Cys heterozygous individuals. Pharmacogenet Genomics (2006) 0.77
Recent structural advances of β1 and β2 adrenoceptors yield keys for ligand recognition and drug design. J Med Chem (2013) 0.77
Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist. Eur J Med Chem (2008) 0.76
Homology modeling and flex-ligand docking studies on the guinea pig beta(2) adrenoceptor: structural and experimental similarities/ differences with the human beta(2). J Mol Model (2009) 0.76
Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor. Bioorg Med Chem (2011) 0.76
Mucosa of human detrusor impairs contraction and β-adrenoceptor-mediated relaxation. BJU Int (2013) 0.76
Energetic and flexibility properties captured by long molecular dynamics simulations of a membrane-embedded pMHCII-TCR complex. Mol Biosyst (2016) 0.76
o-Alkylselenenylated benzoic acid accesses several sites in serum albumin according to fluorescence studies, Raman spectroscopy and theoretical simulations. Protein Pept Lett (2013) 0.76
Molecular modeling study of isoindolines as L-type Ca(2+) channel blockers by docking calculations. J Mol Model (2010) 0.76
Boron-containing compounds: chemico-biological properties and expanding medicinal potential in prevention, diagnosis and therapy. Expert Opin Ther Pat (2014) 0.76
A study of the structural properties and thermal stability of human Bcl-2 by molecular dynamics simulations. J Biomol Struct Dyn (2013) 0.76
Scope and difficulty in generating theoretical insights regarding ligand recognition and activation of the beta 2 adrenergic receptor. J Med Chem (2010) 0.76
Ethers and esters derived from apocynin avoid the interaction between p47phox and p22phox subunits of NADPH oxidase: evaluation in vitro and in silico. Biosci Rep (2013) 0.75
Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus. Bioinformation (2013) 0.75
Seeking potential anticonvulsant agents that target GABAA receptors using experimental and theoretical procedures. J Comput Aided Mol Des (2014) 0.75
Comparison of the effect of chronic cadmium exposure on the antioxidant defense systems of kidney and brain in rat. Toxicol Mech Methods (2013) 0.75
Tyr74 is essential for the formation, stability and function of Plasmodium falciparum triosephosphate isomerase dimer. Arch Biochem Biophys (2009) 0.75
Design, synthesis and in vitro evaluation of (R)-4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenyl hydrogen phenylboronate: a novel salbutamol derivative with high intrinsic efficacy on the β2 adrenoceptor. Bioorg Med Chem Lett (2010) 0.75
Corticosterone microinjected into nucleus pontis oralis increases tonic immobility in rats. Horm Behav (2011) 0.75
N-ω-chloroacetyl-L-ornithine has in-vitro activity against cancer cell lines and in-vivo activity against ascitic and solid tumors. Anticancer Drugs (2016) 0.75
A simple validated RP-HPLC bioanalytical method for the quantitative determination of a novel valproic acid arylamide derivative in rat hepatic microsomes. Biomed Chromatogr (2014) 0.75
Exploring the ligand recognition properties of the human vasopressin V1a receptor using QSAR and molecular modeling studies. Chem Biol Drug Des (2013) 0.75
Comparing the electronic properties and docking calculations of heme derivatives on CYP2B4. J Mol Model (2008) 0.75
Evaluation of new antimicrobial agents on Bacillus spp. strains: docking affinity and in vitro inhibition of glutamate-racemase. J Enzyme Inhib Med Chem (2012) 0.75
p-Aminobenzoic acid derivatives as acetylcholinesterase inhibitors. Eur J Med Chem (2005) 0.75
Toward a rational design of selective multi-trypanosomatid inhibitors: a computational docking study. Bioorg Med Chem Lett (2006) 0.75
Molecular modeling and QSAR studies for drug design. Curr Pharm Des (2013) 0.75
In vitro effect of H2O 2, some transition metals and hydroxyl radical produced via fenton and fenton-like reactions, on the catalytic activity of AChE and the hydrolysis of ACh. Neurochem Res (2014) 0.75
Identification of multiple allosteric sites on the M1 muscarinic acetylcholine receptor. FEBS Lett (2005) 0.75
Surprises from a cardiac 5-HT₄TG mouse: spontaneous atrial arrhythmias by endogenous 5-HT of atrial origin? Different mechanism of arrhythmias through 5-HT₄ receptors and β-adrenoceptors? Naunyn Schmiedebergs Arch Pharmacol (2013) 0.75